{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:59:19Z","timestamp":1792760359294,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To compare outcomes of women with advanced-stage low-grade serous ovarian cancer and high-grade serous ovarian cancer and identify factors associated with survival among patients with advanced-stage low-grade serous ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>A retrospective study of patients diagnosed with grade 1 or 3, advanced-stage (stage IIIC and IV) serous ovarian cancer between 2003 and 2011 was undertaken using the National Cancer Database, a large administrative database. The effect of grade on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model. Among women with low-grade serous ovarian cancer, propensity score matching was used to compare all-cause mortality among similar women who underwent chemotherapy and lymph node dissection and those who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      A total of 16,854 (95.7%) patients with high-grade serous ovarian cancer and 755 (4.3%) patients with low-grade serous ovarian cancer were identified. Median overall survival was 40.7 months among high-grade patients and 90.8 months among women with low-grade tumors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001). Among patients with low-grade serous ovarian cancer in the propensity score-matched cohort, the median overall survival was 88.2 months among the 140 patients who received chemotherapy and 95.9 months among the 140 who did not receive chemotherapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.7). Conversely, in the lymph node dissection propensity-matched cohort, median overall survival was 106.5 months among the 202 patients who underwent lymph node dissection and 58 months among the 202 who did not (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>When compared with high-grade serous ovarian cancer, low-grade serous ovarian cancer is associated with improved survival. In patients with advanced-stage low-grade serous ovarian cancer, lymphadenectomy but not adjuvant chemotherapy was associated with improved survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000001867","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T06:47:16Z","timestamp":1487832436000},"page":"439-447","source":"Crossref","is-referenced-by-count":144,"title":["Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer"],"prefix":"10.1097","volume":"129","author":[{"given":"Allison","family":"Gockley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Bregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel T.","family":"Clemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Schorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian cancer serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.pgp.0000130446.84670.93","article-title":"Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data","volume":"23","author":"Gilks","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1521","article-title":"In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low grade serous tumours","volume":"202","author":"Sieben","year":"2004","journal-title":"J Pathol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/jnci\/85.18.1513","article-title":"Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer","volume":"85","author":"Kohler","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R10-20230711","first-page":"12","article-title":"Tumor suppressor p53: analysis of wild-type and mutant p53 complexes","volume":"11","author":"Milner","year":"1991","journal-title":"Mol Cell Biol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1525-1438.2007.01039.x","article-title":"Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a much higher mutation rate than previously reported and does not correlate with drug resistance","volume":"18","author":"Salani","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 10","key":"R12-20230711","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann Oncol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Greshenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/gyno.1998.5051","article-title":"Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features\u2014problems involved in the architectural grading system","volume":"70","author":"Shimizu","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for casual effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000615","article-title":"Ovarian low-grade serous carcinoma: a clinicopathologic study of 33 cases with primary surgery performed at a single institution","volume":"40","author":"Okoye","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ygyno.2013.05.021","article-title":"Low-grade serous carcinoma: new concepts and emerging therapies","volume":"130","author":"Romero","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2011.02.017","article-title":"Low-grade serous primary peritoneal carcinoma","volume":"121","author":"Schmeler","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0000000000000742","article-title":"Activity of bevacizumab in patients with low-grade serous ovarian carcinoma","volume":"26","author":"Rose","year":"2016","journal-title":"Int J Gynecol Oncol"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2009.25.3617","article-title":"Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R","article-title":"Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I\/II patients and superior survival to other stage III patients","volume":"83","author":"Onda","year":"1998","journal-title":"Cancer"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201703000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T14:05:18Z","timestamp":1689084318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201703000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001867","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}